Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON) has in-licensed U.S. commercialization rights to HEMANGEOL oral solution, the only FDA-approved treatment for infantile hemangioma that requires systemic therapy. Effective May 1, 2026, Eton will commercialize HEMANGEOL in the U.S. and distribute through its Eton Cares program with a $0 co-pay option for qualifying patients.
The company said the transaction will be financed with cash on hand and is expected to be accretive to 2026 earnings. Pierre Fabre will continue global commercialization and U.S. commercialization through April 30, 2026.
Positive
- Acquired U.S. commercialization rights to HEMANGEOL effective May 1, 2026
- Transaction expected to be accretive to 2026 earnings
- Eton will offer $0 co-pay via Eton Cares to broaden access
- Estimated 5,000–10,000 U.S. infants treated with HEMANGEOL annually
- Eton achieves ten commercial products in its rare disease portfolio
Negative
- Transaction financed with cash on hand, reducing available cash resources
- Pierre Fabre retains U.S. commercialization through April 30, creating transition period
Key Figures
Market Reality Check
Peers on Argus
ETON was down 1.51% pre-news while key peers like KMDA (-1.14%), EOLS (-2.71%), EBS (-0.61%), and AQST (-0.74%) also traded lower, with ESPR up 0.60%. Only AQST appeared on the momentum scanner, suggesting ETON’s acquisition headline is more stock-specific than part of a broad sector move.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 03 | Galzin acquisition | Positive | -9.2% | Acquisition of Galzin for Wilson Disease and expansion of rare disease portfolio. |
| Dec 20 | Increlex deal close | Positive | +2.4% | Closing of Increlex acquisition, adding SPIGFD biologic to rare disease lineup. |
| Nov 25 | Amglidia rights deal | Positive | +7.1% | Acquisition of U.S. rights to Amglidia for neonatal diabetes mellitus. |
| Oct 03 | Increlex purchase pact | Positive | +16.3% | Agreement to acquire Increlex from Ipsen, expanding ultra-rare endocrine portfolio. |
| Mar 22 | PKU GOLIKE acquisition | Positive | +9.4% | Acquisition of PKU GOLIKE for phenylketonuria to deepen rare disease focus. |
Acquisition headlines for ETON have generally been followed by positive price moves, with 4 of the last 5 tagged acquisition events showing aligned, positive reactions and one notable negative divergence.
Over the past year, Eton has used acquisitions to expand its rare disease portfolio, including PKU GOLIKE for phenylketonuria, U.S. rights to Amglidia for neonatal diabetes, and multiple steps acquiring Increlex, plus Galzin for Wilson Disease. Price reactions ranged from -9.15% to +16.33%, with most deals drawing positive moves. The new HEMANGEOL U.S. rights fit this ongoing rare disease roll-up strategy.
Historical Comparison
In the last five acquisition-related announcements, ETON’s average 24-hour move was +5.21%, with most deals in rare or ultra-rare diseases, similar to today’s HEMANGEOL transaction.
Acquisitions have steadily broadened Eton’s rare disease portfolio: PKU GOLIKE for phenylketonuria, Amglidia for neonatal diabetes, Galzin for Wilson Disease, and staged Increlex deals, now complemented by HEMANGEOL for infantile hemangioma.
Market Pulse Summary
This announcement adds HEMANGEOL, the only FDA-approved systemic therapy for infantile hemangioma, to Eton’s rare disease portfolio, with an estimated 5,000–10,000 U.S. infants treated annually and $11.7 million in 2025 U.S. sales. The deal includes a $14.0 million upfront payment and inventory purchases funded from cash, with management expecting 2026 earnings accretion. Investors may track the May 1 commercialization handoff and integration into the Eton Cares program.
Key Terms
orphan drug regulatory
systemic therapy medical
hypoglycemia medical
AI-generated analysis. Not financial advice.
- HEMANGEOL® is the only FDA-approved treatment for infantile hemangioma
- HEMANGEOL will be commercialized by Eton beginning May 1st
- HEMANGEOL will be distributed through the company’s Eton Cares™ patient support program, which includes a
$0 co-pay initiative, to broaden patient access.
DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas (“Pierre Fabre”). HEMANGEOL is an Orphan Drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.
“As the only treatment for infantile hemangiomas that require systemic therapy, HEMANGEOL is a critical medication and a strong fit with Eton’s orphan-focused commercial model. We look forward to expanding access to treatment by incorporating our Eton Cares patient support program, which includes our
“With this acquisition and the recent approval of DESMODA™ (desmopressin acetate), Eton has now achieved its long-held goal of ten commercial products,” Brynjelsen continued. “This major milestone reflects our continued progress toward building the largest rare disease portfolio in the United States.”
Infantile hemangiomas are non-cancerous vascular tumors which typically appear in the first days or weeks of a newborn’s life. In severe cases, infantile hemangiomas can lead to serious complications including loss of vision, trouble breathing, or physical deformities, and require intervention with systemic therapy. Treatment with HEMANGEOL is typically initiated between ages five weeks to five months and continues for approximately six months. It is estimated that approximately 5,000-10,000 infants are treated with HEMANGEOL annually in the United States.
The transaction is expected to be accretive to 2026 earnings and will be financed with the company’s cash on hand. Pierre Fabre will continue commercializing HEMANGEOL globally, and in the U.S. until April 30. Effective May 1, Eton will commercialize HEMANGEOL in the U.S. Eton plans to administer the Company’s best-in-class Eton Cares Program which provides prescription fulfillment, insurance benefits investigation, educational support, financial assistance for qualified patients, and other services designed to help patients access treatment. Eton Cares will offer co-pay assistance with
For more information about the product, patients and healthcare professionals can call Eton Pharmaceuticals at (847) 787-7361.
Important Safety Information for HEMANGEOL
Do not give HEMANGEOL to your child if your child:
- was born prematurely and has not reached the corrected age of 5 weeks
- weighs less than 4 ½ pounds
- is allergic to propranolol or any of the other ingredients in HEMANGEOL
- has asthma or a history of breathing problems
- has a heart problem, slow heart rate (less than 80 heart beats per minute), very low blood pressure
- is at risk for low blood sugar, for example is vomiting or unable to take feedings
- has high blood pressure caused by a tumor on the adrenal gland, called “pheochromocytoma”
Tell your doctor about all of your child’s medical conditions, all of the medicines your child takes, and all of the medicines that you take if you are breastfeeding your child.
HEMANGEOL can cause serious side effects, including:
Low blood sugar (hypoglycemia), especially if your child is not taking feedings, or is vomiting. HEMANGEOL may make it more difficult to recognize the signs and symptoms of low blood sugar in your child. To help reduce the risk of low blood sugar with HEMANGEOL, give HEMANGEOL during or shortly after feeding your child. Feed your child regularly during treatment. Tell your doctor if your child has a poor appetite. If your child is not taking feedings, due to an illness or vomiting, do not give HEMANGEOL until your child is taking feedings normally again.
If your child has any of the signs or symptoms of low blood sugar listed below during treatment with HEMANGEOL, stop giving your child HEMANGEOL and call your doctor or go to the nearest emergency room right away.
Signs or symptoms of low blood sugar include: pale, blue or purple skin color, sweating, irritability, crying for no apparent reason, irregular or fast heartbeat, poor feeding, low body temperature, unusual sleepiness, seizures, breathing stops for short periods of time, and loss of consciousness
If your child is conscious, give him/her a drink of a liquid containing sugar.
Other serious side effects can include:
- New or worsening slow heart rate (bradycardia) or low blood pressure (hypotension).
- Breathing problems or wheezing.
- Stroke. HEMANGEOL may increase the risk of stroke in certain children who have severe problems with the blood vessels in their brain, particularly if your child has a large hemangioma that affects the face or head.
Call your doctor or go to the nearest hospital emergency room if your child has:
- pale skin color, slow or uneven heartbeats, arms or legs feel cold, blue or purple skin color, or fainting.
- breathing problems or wheezing during treatment with HEMANGEOL.
The most common side effects include: sleep problems, worsening respiratory tract infections, diarrhea, and vomiting.
These are not all the possible side effects of HEMANGEOL. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see Full Prescribing Information and Medication Guide.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVITM, INCRELEX®, ALKINDI SPRINKLE®, DESMODA™, GALZIN®, HEMANGEOL®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When will Eton (ETON) begin U.S. commercialization of HEMANGEOL?
How will Eton distribute HEMANGEOL and support patient access (ETON)?
What is the financial impact of the HEMANGEOL deal on Eton's 2026 earnings (ETON)?
How many U.S. infants are treated with HEMANGEOL each year?
Does Pierre Fabre continue any HEMANGEOL commercialization after the deal?
